CLINICAL_TRIALS
trial_result
· 2025-03-12
Clinical Trial Update: A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants [Phase 1]
Summary
Vaxxinity reports Phase 1 results assessing the safety, tolerability, and immunogenicity of UB-313 in healthy participants for migraine.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vaxxinity, Inc. | Conditions: Migraine | Phase 1 | Status: COMPLETED | Results posted: 2025-03-12